Home  »  Finance   »  Investors Considering Selling TScan Therapeutics I...

Investors Considering Selling TScan Therapeutics Inc. (TScan Therapeutics Inc.:TCRX) Holdings?

TScan Therapeutics Inc. (NASDAQ:TCRX) traded at $2.08 at close of the session on Monday, 01/23/23, made a downward move of -0.95% on its previous day’s price.

Looking at the stock we see that its previous close was $2.10 with the day’s price range being $1.95 – $2.67. In terms of its 52-week price range, TCRX has a high of $5.60 and a low of $1.45. The company’s stock has gained about 30.00% over that past 30 days.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

TScan Therapeutics Inc. has a market cap of $49.63 million. Estimates by analysts give the company expected earnings per share (EPS) of -$0.72, with the EPS growth for the year raised at -$2.88 for 2022 and -$2.85 for next year. These figures represent 30.90% and 1.00% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $3.7 million, with a low of $3 million and a high of $4.46 million. The median projection represents growth squeezing down to 52.30% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $13.72 million, or 35.30% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the TCRX stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 5 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the TScan Therapeutics Inc. (TCRX) stock as a Hold, while 4 rate it as a Buy. 1 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is 15.14% off its SMA20 and 0.75% from its 50-day simple moving average. The RSI (14) is pointing at 53.57 while the volatility over the past week is 20.18% and jumps to 17.09% over the past one month. The average price target for the stock over the next 12 months is $14.00, with the estimates having a low of $6.00 and a high of $21.00. These price ends are -188.46% and -909.62% off the current price level respectively, although investors could be excited at the prospect of a -597.12% if the TCRX share price touches on the median price of $14.50.

Coming back to TScan Therapeutics Inc. (NASDAQ:TCRX), we note that the average 3-month trading volume was 26.68K, while that of the preceding 10-day period stands at 26990.0. Current shares outstanding are 24.07 million.

The insiders hold 7.00% of the company’s shares while institutions hold 63.50%. The data shows that short shares as of Oct 13, 2022, stood at 55680.0 at a short ratio of 4.09. This represents a 0.23% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 53210.0. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 34.19% up in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *